Surrogate Endpoints for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: Results from the Individual Patient Data Meta-Analysis Mac-Npc2

F. Rotolo,P. Pignon,S. Marguet,J. Ma,A. T. C. Chan,P-Y. Huang,G. Zhu,D. T. Chua,Y. Chen,H-Q. Mai,D. W. Kwong,Y. L. Soong,J. Moon,Y. Tung,K-H. Chi,G. Fountzilas,L. Zhang,A. Lee,P. Blanchard,S. Michiels

DOI: https://doi.org/10.1093/jnci/djw239

2017-01-01

JNCI Journal of the National Cancer Institute

Abstract:Background: Our objective was to evaluate progression-free survival (PFS) and distant metastasis-free survival (DMFS) as surrogate end points for overall survival (OS) in randomized trials of chemotherapy in loco-regionally advanced nasopharyngeal carcinomas (NPCs).Methods: Individual patient data were obtained from 19 trials of the updated Meta-Analysis of Chemotherapy in Nasopharyngeal Carcinoma (MAC-NPC) plus one additional trial (total = 5144 patients). Surrogacy was evaluated at the individual level using a rank correlation coefficient rho and at the trial level using a correlation coefficient R-2 between treatment effects on the surrogate end point and OS. A sensitivity analysis was performed with two-year PFS/DMFS and five-year OS.Results: PFS was strongly correlated with OS at the individual level (rho = 0.93, 95% confidence interval [CI] = 0.93 to 0.94) and at the trial level (R-2 = 0.95, 95% CI = 0.47 to 1.00). For DMFS, too, the individual-level correlation with OS was strong (rho = 0.98, 95% CI = 0.98 to 0.98); at trial level, the correlation was high but the regression adjusted for measurement error could not be computed (unadjusted R-2 = 0.96, 95% CI = 0.94 to 0.99). In the sensitivity analysis, two-year PFS was highly correlated with five-year OS at the individual level (rho = 0.89, 95% CI = 0.88 to 0.90) and at the trial level (R-2 = 0.85, 95% CI = 0.46 to 1.00); two-year DMFS was highly correlated with five-year OS at the individual level (rho = 0.95, 95% CI = 0.94 to 0.95) and at the trial level (R-2 = 0.78, 95% CI = 0.33 to 1.00).Conclusions: PFS and DMFS are valid surrogate end points for OS to assess treatment effect of chemotherapy in loco-regionally advanced NPC, while PFS can be measured earlier.